VEGFA and cancer: Notably, Bevacizumab(anti-VEGF), an FDA-approved drug for previously untreated metastatic colorectal cancer, has demonstrated remarkable effects, extending its application to diverse malignant tumors, including NSCLC, renal cell carcinoma, ovarian cancer, and cervical cancer (215, 217).